Matthew P. Cheng

Academic title(s): 


Assistant Professor | McGill University

Transplant Infectious Diseases | Medical Mycology

Royal Victoria Hospital | McGill University Health Centre

Matthew P. Cheng
Contact Information

Royal Victoria Hospital | McGill University Health Centre

1001 Decarie Blvd EM3.3218 | Montreal QC | H4A 3J1

Email address: 
matthew.cheng [at]
Associate Members
Epidemiology & Infectious Diseases
Graduate supervision: 



Dr. Cheng obtained his medical degree from McGill University, and then subsequently completed his residency in internal medicine at the University of British Columbia. He then returned to McGill to complete a combined fellowship in infectious diseases and medical microbiology. Afterwards, he completed a postdoctoral fellowship at the Harvard Medical School-affiliated Brigham and Women's Hospital and Dana-Farber Cancer Institute under the mentorship of Francisco Marty and Jerry Ritz before establishing his clinical research program at the McGill University Health Centre. His research program is funded by research operating grants from the US National Institutes of Health, the Canadian Institutes for Health Research, and the Australian National Health and Medical Research Council.

Awards, honours, and fellowships: 

He is the recipient of several fellowship grants from the Royal College of Physicians and Surgeons of Canada, the Association of Medical Microbiologists and Infectious Diseases Specialists of Canada, as well as the Fonds de Recherche Santé Quebec. He has received numerous awards including Top Influential Article in Blood Advances (2021), paper of the year by the Fédération des Médecins Spécialistes du Québec (2020), and Best Abstract Award by the Infectious Diseases Society of America (2019). He was also awarded the prestigious Terry Fox Humanitarian Award.

Current research: 

His research focuses on patients with potentially lethal infections, including those with severe manifestations of sepsis, bloodstream infections, and opportunistic infections in immunocompromised hosts. His program focuses on improving morbidity and mortality in these conditions by discovering original treatment strategies through avant-garde clinical trials. He also develops novel diagnostic assays to improve outcomes in these patients, such as using plasma cell-free DNA to monitor the host-response to infection and optimize treatment decisions.

Selected publications: 
Back to top